But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately. Eli Lilly is planning to further fuel demand with new consumer-focused advertising in the coming weeks. Lilly and Novo are fighting to end compounding, publicly arguing it is about protecting patient health. In October, the FDA announced that Lilly had finally produced enough tirzepatide to meet soaring demand. It could be a matter of months, but Eli Lilly and Novo Nordisk may soon get what they want.

Source: Wall Street Journal November 18, 2024 09:24 UTC